



Rajiv Gandhi Cancer Institute
and Research Centre

BREAST CANCER UPDATE 2024

(From the Lens of ASCO, ESMO & SABCS)

15th June 2024 - Pearl Ballroom, 3rd Floor,
Hotel Crowne Plaza, Rohini, New Delhi

16th June 2024 - Indraprastha Hall, RGCIRC, Rohini, New Delhi



Managed by **MIGHTY DUO**.

BREAST CANCER UPDATE 2024



Rajiv Gandhi Cancer Institute
and Research Centre

DEAR COLLEAGUE,

WE ARE DELIGHTED TO EXTEND OUR HEARTFELT INVITATION TO YOU FOR THE BREAST CANCER UPDATE CONFERENCE 2024, WHERE WE WILL BE EXPLORING THE LATEST INSIGHTS AND BREAKTHROUGHS PRESENTED AT THE PRESTIGIOUS ASCO, ESMO, AND SABCS INTERNATIONAL MEETINGS. THE CONFERENCE WILL TAKE PLACE IN THE VIBRANT CITY OF DELHI ON JUNE 15TH AND 16TH, 2024.

ABOUT THE CONFERENCE:

THE BREAST CANCER UPDATE CONFERENCE SERVES AS A PLATFORM FOR HEALTHCARE PROFESSIONALS, RESEARCHERS, AND STAKEHOLDERS TO COME TOGETHER AND DELVE INTO THE MOST RECENT ADVANCEMENTS IN BREAST CANCER RESEARCH, DIAGNOSIS, AND TREATMENT. THROUGH COMPREHENSIVE SESSIONS, PANEL DISCUSSIONS, AND INTERACTIVE WORKSHOPS, ATTENDEES WILL GAIN VALUABLE KNOWLEDGE AND INSIGHTS TO ENHANCE THEIR PRACTICE AND CONTRIBUTE TO THE ONGOING FIGHT AGAINST BREAST CANCER.

HIGHLIGHTS INCLUDE:

1. IN-DEPTH ANALYSIS OF KEY FINDINGS AND TRENDS FROM ASCO, ESMO, AND SABCS
2. EXPERT-LED SESSIONS COVERING EMERGING THERAPIES, PRECISION MEDICINE, AND PATIENT-CENTERED CARE
3. NETWORKING OPPORTUNITIES WITH ESTEEMED COLLEAGUES AND THOUGHT LEADERS IN THE FIELD

REGISTRATION FOR THE CONFERENCE IS NOW OPEN. SECURE YOUR SPOT TODAY TO JOIN US FOR THIS ENRICHING AND TRANSFORMATIVE EVENT.

WE LOOK FORWARD TO WELCOMING YOU TO THE BREAST CANCER UPDATE CONFERENCE 2024 IN DELHI AND TOGETHER, ADVANCING OUR COLLECTIVE EFFORTS IN THE FIGHT AGAINST BREAST CANCER.





Organizing Committee

CHIEF PATRON

MR. RAKESH CHOPRA

PATRONS

MR. D S NEGI DR. SUDHIR KUMAR RAWAL DR. A K DEWAN

ORGANIZING CHAIRMAN

DR. D C DOVAL

SCIENTIFIC CHAIRS

DR. ANURAG MEHTA DR. MUNISH GAIROLA

ORGANIZING SECRETARY

DR. PANKAJ GOYAL

CORE ORGANIZING COMMITTEE

DR. RAJEEV KUMAR DR. VINEET TALWAR
DR. VAISHALI ZAMRE DR. ULLAS BATRA
DR. KUNDAN SINGH CHUFAL DR. VISHVAK CHANTHAR

ADVISORY COMMITTEE

DR. PINKY YADAV DR. IRFAN AHMED
DR. SUMIT GOYAL DR. IPSITA BHATTACHARJEE
DR. RAJAT SAHA DR. DHEERAJ
DR. SHEKHAR SAHA DR. NAVNEET SINGH
DR. GARIMA DAGA DR. JASKARAN SINGH SETHI
DR. SUNIL PASRICHA DR. ANJALI PAHUJA
DR. PARTHA S CHAUDHARY DR. PARVEEN AHLAWAT
DR. MANOJ GUPTA DR. ANILA SHARMA
DR. PARVEEN KAUR DR. SAMARTH GUPTA
DR. KAPIL GOYAL



AGENDA (Day 1 - Saturday 15th June 2024) Pearl Ballroom, 3rd Floor, Crowne Plaza, Rohini

03.00 PM - 03.30 PM	Registrations
03.30 PM	Welcome & Context Setting Dr. D C Doval / Dr. Pankaj Goyal
03.30 PM - 04.20 PM	Breast Cancer - Early Stage / LABC
Chairpersons	Dr. Rajesh Vashistha, Bathinda (RO); Dr. Kapil Suri, Delhi (RO)
03.30 PM - 03.35 PM	Abstract 1 - Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial Presenter: Dr. Nita Nair, Mumbai (SO)
03.35 PM - 03.40 PM	Abstract 2 - Invasive disease-free survival across key subgroups from the Phase III NATALEE study of ribociclib + a nonsteroidal aromatase inhibitor in patients with HR + /HER2 - early breast cancer Presenter: Dr. Ankit Batra, Dehradun (MO)
03.40 PM - 03.45 PM	Abstract 3 - 242MO-Association of tumor-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR +) /HER2-negative (HER2-) early breast cancer (BC) - A translational analysis of four prospective multicentric studies. Presenter: Dr. Rakesh Sharma, Delhi (MO)
03.45 PM - 03.50 PM	Abstract 4 - Evolution and prognostic significance of HER-2 changes from primary to residual disease in patients with HER-2-negative breast cancer receiving neoadjuvant chemotherapy. Presenter: Dr. Arpit Jain, Delhi (MO)
03.50 PM - 03.55 PM	Abstract 5 - Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial Presenter: Dr. Sarthak Tandon, Delhi (RO)
03.55 PM - 04.15 PM	Panel Discussion Moderator: Dr. Geeta Kadayaprath, Delhi (SO) Panelists: Dr. Shefali Sardana, Delhi (MO); Dr. Parveen Jain, Delhi (MO); Dr. Manish Sharma, Delhi (MO); Dr. Jyoti Anand, Delhi (MO); Dr. Puneet Nagpal, Faridabad (RO) Dr. Veda Padma Priya, Chennai (SO); Dr. Vikas Talreja, Kanpur (MO); Dr. Suhail Qureshi, Delhi (MO);
04:15 PM - 04.20 PM	Expert's Comments Dr. Asha Reddy Chennai (SO); Dr. Arun Goel, Delhi (SO)
04:20 PM - 04:35 PM	Strategies in Assessing Risk in HR + /HER2- EBC (Novartis) Speaker - Dr. Chandragouda D, Delhi (MO)
04.35 PM - 05.05 PM	Panel Discussion on high risk breast cancer (Eli Lilly) Experts: Dr. Vikas Talreja, Kanpur (MO); Dr. Jatin Sarin, Chandigarh (MO); Dr. Bharat Bhosale, Mumbai (MO)



AGENDA (Day 1 - Saturday 15th June 2024)

05:05 PM- 05.55 PM **Triple Negative Breast Cancer (TNBC)**

Chairpersons

Dr. Roshan Prajapati, Nepal; Dr. Vaishali Zamre, Delhi; Dr. Sunil Kumar Gupta, Delhi (MO)

05.05 PM - 05.10 PM

Abstract 6 - The positive sentinel lymph node: What does it mean for treatment?
The surgeon's perspective
Presenter: Dr. Anupama Mane, Pune (SO)

05.10 PM - 05.15 PM

Abstract 7 - Atezolizumab and tumor microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from Impassion031
Presenter: Dr. Dipen Bhuvra, Delhi (MO)

05.15 PM - 05.20 PM

Abstract 8 - Phase 3 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy, Followed by Adjuvant Pembrolizumab or Placebo Plus Endocrine Therapy for Early-Stage High-Risk ER +/HER2 – Breast Cancer: KEYNOTE-756
Presenter: Dr. Mukesh Bang, Nagpur (MO)

05.20 PM - 05.25 PM

Abstract 9 - PS16-06 Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study
Presenter: Dr. Manisha Singh, Patna (MO)

05.25 PM - 05.30 PM

Abstract 10 - Reconstructive plastic surgery in combined treatment of breast cancer: Predictive risk factors of complications and reconstruction failure.
Presenter: Dr. Samarth Gupta, Delhi (Reconstructive Surgery)

05.30 PM - 05.50 PM

Panel Discussion

Moderator: Dr. Shefali Sardana, Delhi (MO)
Panelists: Dr. Ashish Gupta, Delhi (MO); Dr. Chandragouda D, Delhi (MO); Dr. Kapil Goel, Delhi (MO); Dr. Mudit Aggarwal, Delhi (MO); Dr. Charu Jora, Gurugram (Nuclear Medicine); Dr. Mukesh Patekar, Delhi (MO); Dr. Manoj Tayal, Delhi (RO); Dr. Jalaj Baxi, Delhi (SO); Dr. Anjali K Pahuja, Delhi (RO)

05.50 PM - 05.55 PM

Expert's Comments

Dr. Ashok Vaid, Delhi (MO); Dr. Munish Gairola, Delhi (RO), Dr. Sadashivudu Gundeti, Hyderabad (MO)

05.55 PM - 06.55 PM **Metastatic Breast Cancer (mBC)**

Chairpersons

Dr. Sadashivadu Gundeti, Hyderabad (MO); Dr. Bijesh Ghimire, Nepal; Dr. Rajeev Kumar, Delhi (SO); Dr. Kumardeep Dutta, Delhi (MO)

05.55 PM - 06.00 PM

Abstract 11 - HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer
Presenter: Dr. Ashwin Philip, Kerala (MO)



AGENDA (Day 1 - Saturday 15th June 2024)

06.00 PM - 06.05 PM	Abstract 12 - 482P - Precision imaging with HER2-PET for refined treatment selection in patients with HER2-low breast cancer Presenter: Dr. Manoj Gupta, Delhi (NM)
06.05 PM - 06.10 PM	Abstract 13 - Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBICRG-M06/EMERALD). Presenter: Dr. Novak Gupta, Faridabad (MO)
06.10 PM - 06.15 PM	Abstract 14 - A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03 Presenter: Dr. Rajat Saha, Delhi (MO)
06.15 PM - 06.20 PM	Abstract 15 - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy-naïve, hormone receptor-positive advanced breast cancer in post-menopausal women (FALCON) Presenter: Dr. Akshay Shivchand, Kohlapur (MO)
06.20 PM - 06.25 PM	Abstract 16 - ASCO Giredestrant for Estrogen Receptor-Positive, HER2 -Phase II aceLERA BreastCancer Stud ASCO Presenter: Dr. Priyanshu Chaudhary, Mohali (MO)
06.25 PM - 06.45 PM	Panel Discussion Moderator: Dr. Amish Vora, Delhi (MO) Panelists: Dr. Vibhor Sharma, Noida (Hemat); Dr. Samarth Gupta, Delhi (Plastic Surgeon); Dr. Shalabh Arora, Haldwani (MO); Dr. Abhishek Bansal, Delhi (IR); Dr. Ishu Gupta, Delhi (MO); Dr. Shivashankara MS, Delhi (MO); Dr. Rajat Saha, Delhi (MO); Dr. Praveen Ahlawat, Delhi (RO); Dr. Varun Goel, Delhi (MO); Dr. Sristee Shrestha Prajapati, Nepal
06.45 PM - 06.55 PM	Expert's Comments Dr. Deni Gupta, Delhi (MO); Dr. Sunil Kumar Gupta, Delhi (MO)
06.55 PM - 07.10 PM	A Flexible future : Transforming the Paradigm of HER + BC (Roche) Speaker - Dr. Parveen Jain, Delhi (MO)
07.10 PM - 07.30 PM	Redefining treatment outcomes with immunotherapy Early Triple Negative Breast Cancer (MSD) Speaker - Dr. Shyam Aggarwal, Delhi (MO)
07.30 PM - 07.50 PM	Role of immunotherapy and its sequencing strategy Advanced Triple Negative Breast Cancer (MSD) Speaker - Dr. Vineet Govind Gupta, Delhi (MO)
07.50 PM - 08.30 PM	Miscellaneous
Chairpersons	Dr. Jaskaran Singh Sethi, Delhi (RO); Dr. S P Kataria, Delhi (MO); Dr. Munish Gairola, Delhi (RO), Dr. Vineet Talwar, Delhi (MO)



AGENDA (Day 1 - Saturday 15th June 2024)

- 07.50 PM - 07.55 PM **Abstract 17** - Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study
Presenter: Dr. Chandralekha, Chennai (MO)
- 07.55 PM - 08.00 PM **Abstract 18** - PS16-02 Efficacy and safety of first-line atezolizumab + bevacizumab + paclitaxel in patients with advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Presenter: Dr. A P Dubey, Delhi (MO)
- 08.00 PM - 08.05 PM **Abstract 19** - ASCO Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in TROPION-Breast01 study.
Presenter: Dr. Abhishek Yadav, Delhi (MO)
- 08.05 PM - 08.25 PM **Panel Discussion**
Moderator: Dr. Tarun Durga, Delhi (MO)
Panelists: Dr. Sandeep Ganguly, Kolkata (MO); Dr. Nagendra Sharma, Gurugram (MO); Dr. Sushant Mittal, Delhi (MO); Dr. Kaushal Kalra, Delhi (MO); Dr. Rajat Bajaj, Delhi (MO); Dr. Nithin SG, Delhi (MO); Dr. Swaroopa Mitra, Delhi (RO); Dr. Gagan Saini, Delhi (RO); Dr. Kuldeep Sharma, Delhi (RO); Dr. Deepika Chauhan Delhi, (RO)
- 08.25 PM - 08.30 PM **Expert's Comments**
Dr. Sumit Goyal, Delhi (MO)
- 08.30 PM - 08.45 PM **Dilemma of Choosing a CDK4/6i in 1L mBC Setting – Reality or Myth? (Novartis)**
Speaker - Dr. Vineet Govind Gupta, Delhi (MO)
- 08.45 PM onwards **Valedictory followed by dinner**



AGENDA

(Day 2 - Sunday 16th June 2024)
Indraprastha Hall, RGCIRC, Rohini

10.00 AM - 01.00 PM Patient Survivorship Program

Practical Problems in Cancer Management

Experts:

Dr. D C Doval, Dr. Pinky Yadav, Dr. Vaishali Zamre, Dr. Navneet Singh, Dr. Garima Daga, Dr. Kundan Chufal, Dr. A K Dewan

01.00 PM onwards Lunch

Feel free to contact (Mr. Ravindra Purohit) for any query:
+91 79842 98960, 99985 20100